1
|
van Halteren HK, Bennouna J, Brasiuniene B, Tomas AJC, Trinidad AMG, Indini A, Liposits G, Pellegrino B, Popovic L, Tan A, Vidra R, Strijbos M. Twelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented data. ESMO Open 2023; 8:100773. [PMID: 36634532 PMCID: PMC9843205 DOI: 10.1016/j.esmoop.2022.100773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Revised: 12/05/2022] [Accepted: 12/09/2022] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND During the European Society for Medical Oncology (ESMO) Congress 2022, outcome data of a great number of clinical trials were presented. For the attending medical oncologist, it is important to structure these data in a way that facilitates a trade-off between treatment burden and benefit. MATERIALS AND METHODS To illustrate this, we carried out a narrative non-systematic review of 12 selected oral presentations with potential impact on future daily practice, focusing on trial methodology, possible study flaws, reported clinical benefit and implementability. RESULTS The selected presentations encompassed 10 phase III trials, 1 randomized phase II trial and 1 phase II trial. In 7 out of 12 trials, quality of life and/or patient-reported outcomes had been evaluated. None of the trials, which reported progression-free survival (PFS) data, provided information, which could exclude informative censoring bias. In none of the trials reporting overall survival (OS) data, potential flaws due to undesirable crossover and imbalance between study groups regarding post-progression treatments were addressed. For the 11 reviewed randomized trials, the ESMO-Magnitude of Clinical Benefit Scale (MCBS) grade achieved with the new intervention was calculated based on the presented data. The MCBS grade varied from 1 to 5. CONCLUSIONS Our review confirms the high-quality standard of current cancer research and the clinical relevance of the research questions answered. However, during presentation of PFS and/or OS data, factors known to affect PFS and OS analysis should be structurally addressed. In order to keep cancer care affordable and sustainable, it could be considered to include an ESMO-MCBS threshold in the drug appraisal process of regulatory authorities.
Collapse
Affiliation(s)
- H K van Halteren
- Department of Medical Oncology, Adrz Hospital, Goes, The Netherlands.
| | - J Bennouna
- Department of Medical Oncology, Hospital Foch, Suresnes, France
| | - B Brasiuniene
- Department of Medical Oncology, National Cancer Institute of Lithuania, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - A J Cunquero Tomas
- Department of Medical Oncology, General University Hospital of Valencia, Valencia, Spain; Medical Oncology Unit, General Hospital of Requena, Valencia, Spain
| | - A M Garcia Trinidad
- Section of Medical Oncology, Dagupan Doctors Villaflor Memorial Hospital, Dagupan City, The Philippines
| | - A Indini
- Unit of Medical Oncology, Department of Oncology, Ospedale di Circolo e Fondazione Macchi, ASST Settelaghi, Varese, Italy
| | - G Liposits
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - B Pellegrino
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma; Department of Medical Oncology, University of Parma, Parma, Italy
| | - L Popovic
- Oncology Institute of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
| | - A Tan
- Department of Medical Oncology, Waikato Hospital, Hamilton, New Zealand
| | - R Vidra
- Department of Medical Oncology, Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor", Cluj-Napoca, Romania; UBBMed, Babes-Bolyai University, Cluj-Napoca, Romania
| | - M Strijbos
- Department of Medical Oncology, GZA Hospitals, Wilrijk, Belgium
| |
Collapse
|
2
|
Khan SZ, Garza CV, Sirohi B, Ponde N, Habeeb B, Brandão M, Azim H, Chowdhury A, Spasojevic I, Kovalenko I, Odhiambo A, Seid F, Mutombo A, Petracci F, Vidra R, Mujica SA, Gyawali B, Trapani D, Tagliamento M, Lambertini M. 8P Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|